CureDuchenne Blog

CureDuchenne Ventures is happy to announce its latest investment in Myosana Therapeutics, a new biotech company based in Seattle, WA. Myosana is aiming to develop next-generation gene therapy for Duchenne muscular dystrophy and other neuromuscular […]

Dear Duchenne Community,  I’m truly thrilled about our investment in a new biotech company called Myosana Therapeutics. Myosana aims to develop next-generation gene therapy for Duchenne muscular dystrophy and neuromuscular diseases. Because of this investment, the team is now positioned to conduct […]

Dear Duchenne Community,   We are proud that, through these difficult times, CureDuchenne is continuing to invest in research, to expand our programs and offer services to the Duchenne Community. All of us are feeling the personal, emotional and financial toll […]

Author: Erin Frey, Senior Director of Advocacy, CureDuchenne Watching the news over the last few weeks has ranged from confusing to disheartening, overwhelming and sometimes, let’s admit it, a little […]

Today, we are extremely excited to announce a new partnership with Dyne Therapeutics, an innovative organization whose FORCE™ Platform is working to bring transformational therapies for serious muscle diseases, including […]

View Letter to the Duchenne Community As recently as March 9, CureDuchenne was helping NS Pharma get the word out about their newly launched Expanded Access Program for enabling access […]

THE CURRENT ADVICE FROM THE PROFESSIONAL SOCIETIES IS TO CONTINUE WITH ACE-I AND ARBS. The European Society of Cardiology (ESC) Council on Hypertension announced their stance in a positioning statement […]